Researchers have found in a new study that oral anticoagulants OAC-naive patients experienced a smaller increase in stroke or ...

RyCarma Therapeutics, Inc., a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, has appointed Elizabeth Tarka, M.D., ...

Bayer's AI Innovation Platform (AIIP), powered by Google Cloud technology, streamlines the development of AI-driven medical ...

BMS is a longstanding player in cardiovascular with drugs like Pfizer-partnered Eliquis (apixaban ... which are both based on novel mechanisms of action – have been keenly anticipated by ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study suggests. The IMPROVE study investigated whether a ...